Sponsor: NRG
Sponsor Study ID: NRG-GI011
Study Title: NRG-GI011, A Phase III Randomized Trial of Dose Escalated Radiation in Locally Advanced Pancreas Cancer (LAPC) Patients (LAP100)
CTO #: 104238
NCT Number: NCT06958328
Phase: III
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Pancreas
Study Objectives: To evaluate whether dose-escalated RT improves 3-year overall survival (OS) compared to standard treatments without dose-escalated RT, in locally advanced pancreatic cancer patients without radiographic progression and with biochemical response after an initial interval of chemotherapy.